The specificity for prostate cancer detection on biopsy could be improved by fixing the sensitivity at 95%, with individual specificities of 15% for PSGR, 17% for PCA3, and 34% for the PSGR and PCA3 duplex panel [134]. This evidence concerns the gene OR51E2 and prostate carcinoma.